Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results

被引：0

作者：

Armstrong, April W. ^{[1
]}

Lebwohl, Mark ^{[2
]}

Warren, Richard B. ^{[3
,4
]}

Sofen, Howard ^{[5
]}

Imafuku, Shinichi ^{[6
]}

Ohtsuki, Mamitaro ^{[7
]}

Spelman, Lynda ^{[8
]}

Passeron, Thierry ^{[9
]}

Papp, Kim A. ^{[10
,11
]}

Kisa, Renata M. ^{[12
]}

Berger, Victoria ^{[12
,13
]}

Vritzali, Eleni

Hoyt, Kim ^{[12
]}

Colombo, Matthew J. ^{[12
]}

Banerjee, Subhashis ^{[12
]}

Strober, Bruce ^{[14
]}

Thaci, Diamant ^{[15
]}

Blauvelt, Andrew ^{[16
]}

机构：

[1] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA

[2] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA

[3] Northern Care Alliance NHS Fdn Trust, Dermatol Ctr, Manchester, England

[4] Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Manchester Biomed Res Ctr, Manchester, Lancs, England

[5] Univ Calif Los Angeles, Sch Med & Dermatol Res Associates, Los Angeles, CA USA

[6] Fukuoka Univ, Fac Med, Fukuoka, Japan

[7] Jichi Med Univ, Tochigi, Japan

[8] Verac Clin Res, Brisbane, Qld, Australia

[9] Univ Cote Azur, Univ Hosp Nice, Nice, France

[10] Alliance Clin Res & Prob Med Res, Waterloo, ON, Canada

[11] Univ Toronto, Toronto, ON, Canada

[12] Bristol Myers Squibb, Princeton, NJ USA

[13] Bristol Myers Squibb, Sissach, Switzerland

[14] Yale Univ, New Haven, CT USA

[15] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany

[16] Oregon Med Res Ctr, Portland, OR USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0261

引用

页码：509 / 511

页数：3

共 50 条

[1] Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials
Lebwohl, Mark
Warren, Richard B.
Sofen, Howard
Imafuku, Shinichi
Paul, Carle
Szepietowski, Jacek C.
Spelman, Lynda
Passeron, Thierry
Vritzali, Eleni
Napoli, Andrew
Kisa, Renata M.
Buck, Alex
Banerjee, Subhashis
Thaci, Diamant
Blauvelt, Andrew
BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (05) : 668 - 679
[2] Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program
Spelman, Lynda
Warren, Richard B.
Sofen, Howard
Imafuku, Shinichi
Blauvelt, Andrew
Toms, Jessica
Buck, Alex
Banerjee, Subhashis
Menter, Alan
Szepietowski, Jacek C.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 28 - 28
[3] DEUCRAVACITINIB LONG-TERM EFFICACY AND SAFETY IN PLAQUE PSORIASIS: 2-YEAR RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM
Warren, R. B.
Sofen, H.
Imafuku, S.
Szepietowski, J.
Blauvelt, A.
Spelman, L.
Colston, E.
Toms, J.
Buck, A.
Banerjee, S.
Menter, A.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 841 - 841
[4] Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Program
Warren, Richard
Sofen, Howard
Imafuku, Shinichi
Szepietowski, Jacek C.
Blauvelt, Andrew
Spelman, Lynda
Toms, Jessica
Buck, Alex
Banerjee, Subhashis
Menter, Alan
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4230 - 4232
[5] Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta-analysis
Hu, Caixia
Han, Xiaomei
Cui, Yu
Zhang, Yan
Cheng, Yi
SKIN RESEARCH AND TECHNOLOGY, 2024, 30 (08)
[6] Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 1
Tyring, S.
Spelman, L.
Igarashi, A.
Ohtsuki, M.
Li, Q.
Mendelsohn, A.
Parno, J.
Guenthner, S.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 61 - 61
[7] Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 2
Gooderham, M.
Papp, K.
Blauvelt, A.
Thaci, D.
Li, Q.
Mendelsohn, A.
Parno, J.
Reich, K.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 61 - 62
[8] Deucravacitinib (Sotyktu™) for plaque psoriasis
Granau, Agnete Marie
Boye, Theresa Louise
Jensen, Kim Bak
Nielsen, Ole Haagen
TRENDS IN PHARMACOLOGICAL SCIENCES, 2023, 44 (04) : 252 - 253
[9] DEUCRAVACITINIB IN PLAQUE PSORIASIS: 2-YEAR LABORATORY RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM
Korman, N. J.
Passeron, T.
Gordon, K. B.
Okubo, Y.
Bagel, J.
Sofen, H.
Warren, R. B.
Bhatia, N.
Spelman, L.
Winthrop, K.
Hippeli, L.
Kisa, R. M.
Banerjee, S.
Thaci, D.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1774 - 1775
[10] Deucravacitinib (Sotyktu) for Plaque Psoriasis
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1670): : 29 - 31

← 1 2 3 4 5 →